Use of prazosin in management of hypertension in patients with chronic renal failure and in renal transplant recipients
- PMID: 811312
- PMCID: PMC1675321
- DOI: 10.1136/bmj.4.5994.432
Use of prazosin in management of hypertension in patients with chronic renal failure and in renal transplant recipients
Abstract
Prazosin was used in combination with other antihypertensive drugs in the successful management of hypertension in seven patients with chronic renal failure and six renal transplant recipients, also with chronic renal failure. The addition of small doses of prazosin (mean 3 mg/day) to the antihypertensive regimen produced significant falls in systolic and diastolic blood pressures in both the lying and standing positions. The standing blood pressures were significantly lower than the lying blood pressures during prazosin treatment. Neither the mean blood urea concentrations nor the mean plasma creatinine concentrations changed significantly during prazosin administration. Chromium-51 edetic acid clearances did not change significantly during prazosin treatment in the seven patients in whom it was measured. Severe symptomatic postural hypotension occurred in one patient a week after starting prazosin 3 mg/day. This hypotensive episode was associated with a transient and reversible deterioration in renal function. Another patient developed a rash while on prazosin but it was probably related to propranolol rather than prazosin. Prazosin is thus an effective antihypertensive drug in patients with chronic renal failure, and it may be used with a variety of other drugs. It should be used cautiously, however, since patients with chronic renal failure may respond to small doses, and significant postural falls in blood pressure may result. There was no evidence that the use of prazosin resulted in progressive deterioration in the residual renal function of the patients with chronic renal failure.
Similar articles
-
Double-blind studies of the clinical effectiveness of prazosin.Postgrad Med. 1975 Nov;Spec No:81-7. Postgrad Med. 1975. PMID: 1105489 Clinical Trial.
-
A three-phase clinical evaluation of prazosin.Postgrad Med. 1975 Nov;Spec No:53-60. Postgrad Med. 1975. PMID: 1105485 Clinical Trial.
-
Antihypertensive effect of prazosin in combination with methyldopa, clonidine, or propranolol.Ann Clin Res. 1979 Feb;11(1):18-24. Ann Clin Res. 1979. PMID: 453775 Clinical Trial.
-
Combined alpha- and beta-receptor inhibition in the treatment of hypertension.Drugs. 1984;28 Suppl 2:51-68. doi: 10.2165/00003495-198400282-00005. Drugs. 1984. PMID: 6151891 Review.
-
Treatment of renal hypertension.Clin Nephrol. 1975 Nov;4(5):194-7. Clin Nephrol. 1975. PMID: 167 Review.
Cited by
-
The pharmacokinetics of doxazosin in patients with hypertension and renal impairment.Br J Clin Pharmacol. 1990 Apr;29(4):417-22. doi: 10.1111/j.1365-2125.1990.tb03659.x. Br J Clin Pharmacol. 1990. PMID: 2139337 Free PMC article.
-
Prazosin: a review of its pharmacological properties and therapeutic efficacy in hypertension.Drugs. 1977 Sep;14(3):163-97. doi: 10.2165/00003495-197714030-00002. Drugs. 1977. PMID: 143363 Review. No abstract available.
-
Renal effects of antihypertensive drugs.Drugs. 1989 Jun;37(6):900-25. doi: 10.2165/00003495-198937060-00005. Drugs. 1989. PMID: 2667938 Review.
References
-
- Br Med J. 1974 May 11;2(5914):298-300 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources